Vivanza Biosciences Reports Record Sales Amid Cash Flow Concerns and Market Momentum Shift

Vivanza Biosciences, a microcap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment reflecting its performance in the quarter ending September 2025. The company reported its highest net sales at Rs 55.36 crore, alongside notable increases in key financial metrics such as PBDIT, PBT less other income, PAT, and EPS, all reaching their peak levels for the quarter. This positive financial performance marks a significant turnaround for Vivanza, showcasing its ability to generate revenue effectively.
However, the company faces challenges, particularly in its operating cash flow, which recorded a low of Rs -2.47 crore. This aspect raises concerns about the sustainability of its financial health despite the recent successes in sales and profitability.

In terms of market performance, Vivanza's stock has shown a notable return over the past week, outperforming the Sensex significantly. While the stock has faced declines over longer periods, the recent quarterly results indicate a potential shift in momentum. The company's current price stands at Rs 2.17, reflecting a positive trend compared to its previous close. Overall, Vivanza Biosciences is navigating a complex landscape, balancing strong sales performance with cash flow challenges.